The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

Robert King Biography and Net Worth

Insider of Alector

Robert has served as our Chief Development Officer since January 2017. Robert joined Alector from SciClone Pharmaceuticals, Inc. (acquired by a consortium led by GL Capital Partners, LLC), a biotechnology company, where he served as Senior Vice President of Product Development and Supply Chain from June 2011 to January 2017. Prior to SciClone Pharmaceuticals, Robert served as VP of Product Development and Manufacturing at biotechnology company Bayhill Therapeutics, Inc. from 2006 to 2011. Robert served as VP Product Development and Manufacturing at biotechnology company Rinat Neuroscience Corp. (acquired by Pfizer), from 2003 to 2006. Robert served in positions of increasing responsibility at COR Therapeutics, Inc. (acquired by Millennium Pharmaceuticals, Inc. in 2002) from 1993 to 2003. From 1991 to 1993, Robert served as a Scientist in the Purification and Pharmaceutical Sciences groups at California Biotechnology/Scios. From 1988 to 1991, Robert was a Scientist at Molecular Devices Corporation. Robert holds a Ph.D. in Chemical Engineering from the University of California, Berkeley, and a B.S. in Chemical Engineering from the University of Washington.

What is Robert King's net worth?: The estimated net worth of Robert King is at least $2.70 million as of June 2nd, 2022. Dr. King owns 529,471 shares of Alector stock worth more than $2,695,007 as of April 20th. This net worth evaluation does not reflect any other assets that Dr. King may own. Learn More about Robert King's net worth.
How do I contact Robert King?: The corporate mailing address for Dr. King and other Alector executives is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. Alector can also be reached via phone at (415) 231-5660 and via email at [email protected]. Learn More on Robert King's contact information.
Has Robert King been buying or selling shares of Alector?: Robert King has not been actively trading shares of Alector during the last ninety days. Most recently, Robert King sold 177 shares of the business's stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $8.71, for a transaction totalling $1,541.67. Following the completion of the sale, the insider now directly owns 529,471 shares of the company's stock, valued at $4,611,692.41. Learn More on Robert King's trading history.
Who are Alector's active insiders?: Alector's insider roster includes Robert King (Insider), Robert Paul (Insider), Arnon Rosenthal (CEO), Richard Scheller (Director), Shehnaaz Suliman (COO), and Calvin Yu (VP). Learn More on Alector's active insiders.
Are insiders buying or selling shares of Alector?: During the last year, insiders at the sold shares 13 times. They sold a total of 587,366 shares worth more than $3,536,439.63. The most recent insider tranaction occured on March, 4th when CFO Marc Grasso sold 5,716 shares worth more than $39,554.72. Insiders at Alector own 14.0% of the company. Learn More about insider trades at Alector.
Information on this page was last updated on 3/4/2024.

Robert King Insider Trading History at Alector

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/2/2022	Sell	177	$8.71	$1,541.67	529,471
3/1/2022	Sell	287	$15.57	$4,468.59
1/21/2020	Sell	14,997	$22.01	$330,083.97	507,320
11/15/2019	Sell	7,500	$15.46	$115,950.00

Robert King Buying and Selling Activity at Alector

Alector Company Overview

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Today's Range

Now: $5.09

$4.95

$5.21

50 Day Range

MA: $6.21

$5.07

$7.41

2 Week Range

Now: $5.09

$3.66

$9.06

Volume

473,695 shs

Average Volume

692,224 shs

Market Capitalization

$487.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79